Adherex Receives Regulatory Clearance for Phase II Trial of ADH-1 in Canada

Adherex Technologies Inc., a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Health Canada has given regulatory clearance for the company's Phase II clinical trial application (CTA) for ADH-1, the company's lead antitumor biotechnology compound, also known as Exherin. The Phase II trial, which is expected to involve up to three cancer centers in Canada, will investigate repeated doses of ADH-1 in an every three week dosing schedule in patients whose tumors express the molecular target N-cadherin.

Yahoo News (http://biz.yahoo.com/bw/050324/245226_1.html)